DE60123294D1 - Diazepan Derivate als Faktor X Inhibitor - Google Patents

Diazepan Derivate als Faktor X Inhibitor

Info

Publication number
DE60123294D1
DE60123294D1 DE60123294T DE60123294T DE60123294D1 DE 60123294 D1 DE60123294 D1 DE 60123294D1 DE 60123294 T DE60123294 T DE 60123294T DE 60123294 T DE60123294 T DE 60123294T DE 60123294 D1 DE60123294 D1 DE 60123294D1
Authority
DE
Germany
Prior art keywords
inhibitor
factor
diazepan derivatives
diazepan
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60123294T
Other languages
English (en)
Other versions
DE60123294T2 (de
Inventor
Fukushi Hirayama
Hiroyuki Koshio
Tsukasa Ishihara
Norio Seki
Shunichiro Hachiya
Keizo Sugasawa
Yuji Koga
Ryota Shiraki
Yuzo Matsumoto
Takeshi Shigenaga
Souchirou Kawazoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18611560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60123294(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DE60123294D1 publication Critical patent/DE60123294D1/de
Application granted granted Critical
Publication of DE60123294T2 publication Critical patent/DE60123294T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60123294T 2000-03-31 2001-03-29 Diazepan Derivate als Faktor X Inhibitor Expired - Lifetime DE60123294T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000096858 2000-03-31
JP2000096858 2000-03-31

Publications (2)

Publication Number Publication Date
DE60123294D1 true DE60123294D1 (de) 2006-11-02
DE60123294T2 DE60123294T2 (de) 2007-04-05

Family

ID=18611560

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60103390T Expired - Lifetime DE60103390T2 (de) 2000-03-31 2001-03-29 Diazepinderivate oder deren salze
DE60123294T Expired - Lifetime DE60123294T2 (de) 2000-03-31 2001-03-29 Diazepan Derivate als Faktor X Inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60103390T Expired - Lifetime DE60103390T2 (de) 2000-03-31 2001-03-29 Diazepinderivate oder deren salze

Country Status (21)

Country Link
US (3) US6642224B1 (de)
EP (2) EP1273575B1 (de)
JP (1) JP3788349B2 (de)
KR (1) KR100739359B1 (de)
CN (1) CN1226292C (de)
AR (1) AR027985A1 (de)
AT (2) ATE267178T1 (de)
AU (2) AU776053B2 (de)
BR (1) BR0101264A (de)
CA (1) CA2395846C (de)
DE (2) DE60103390T2 (de)
DK (1) DK1273575T3 (de)
ES (2) ES2217129T3 (de)
HU (1) HUP0101333A3 (de)
MX (1) MXPA01003279A (de)
PL (1) PL207651B1 (de)
PT (1) PT1273575E (de)
RU (1) RU2257381C2 (de)
TR (1) TR200401955T4 (de)
TW (1) TW575569B (de)
WO (1) WO2001074791A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259485B1 (de) * 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. Benzamide und ähnliche inhibitoren vom faktor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
DE60130771T2 (de) 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
PL204898B1 (pl) * 2000-11-22 2010-02-26 Astellas Pharma Inc Podstawiona pochodna benzenu i zawierająca ja kompozycja farmaceutyczna oraz jej zastosowanie
EP1379506A2 (de) 2000-11-28 2004-01-14 Eli Lilly And Company Substituierte carbonsäureamide
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1456175A1 (de) 2001-12-07 2004-09-15 Eli Lilly And Company Substituierte heterozyklische karboxamide mit antithrombotischer aktivität
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
CN1809346A (zh) * 2003-06-18 2006-07-26 默克专利股份公司 作为凝血因子xa和viia的抑制剂用于治疗形成血栓的1－[(4－乙炔基苯基) ]－2－[(苯基)]－吡咯烷－1,2－二酰胺衍生物
US7511066B2 (en) 2003-09-30 2009-03-31 Eli Lilly And Company Antithrombotic aromatic ethers
US7700628B2 (en) 2004-11-24 2010-04-20 Eli Lilly And Company Aromatic ether derivatives useful as thrombin inhibitors
EP1819693B1 (de) 2004-11-29 2009-08-26 Eli Lilly And Company Antithrombotische diamide
JP4900238B2 (ja) 2005-02-02 2012-03-21 味の素株式会社 新規ベンズアミジン化合物
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
TW200734304A (en) 2005-11-08 2007-09-16 Astellas Pharma Inc Benzene derivative or salt thereof
EP2077995B1 (de) * 2006-11-02 2012-02-08 Millennium Pharmaceuticals, Inc. Verfahren zur synthetisierung pharmazeutischer salze aus einem faktor-xa-hemmer
JP2010120852A (ja) * 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
KR20110036833A (ko) 2008-07-11 2011-04-11 아지노모토 가부시키가이샤 아미딘 유도체
TW201021832A (en) * 2008-09-30 2010-06-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
EP2591354B1 (de) * 2010-07-07 2016-09-07 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130261130A1 (en) * 2010-11-01 2013-10-03 Shaheen Ahmed Neurotrypsin inhibitors
WO2013161871A1 (ja) * 2012-04-25 2013-10-31 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417200A (en) * 1994-01-25 1995-05-23 Wasielewski; John J. Lantern cooker
ES2193202T3 (es) 1994-12-02 2003-11-01 Yamanouchi Pharma Co Ltd Nuevo derivado de amidinonaftilo o sal de este.
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
AU8269398A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
CA2294126A1 (en) 1997-06-26 1999-01-07 Douglas Wade Beight Antithrombotic agents
US6372759B1 (en) 1997-06-26 2002-04-16 Eli Lilly And Company Antithrombotic agents
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
JP3811006B2 (ja) 1997-12-19 2006-08-16 シエーリング アクチエンゲゼルシャフト 抗凝血物質類としてのオルト−アントラニルアミド誘導体類
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
US6610704B1 (en) 1998-12-23 2003-08-26 Eli Lilly And Company Antithrombotic amides
ES2226485T3 (es) 1998-12-23 2005-03-16 Eli Lilly And Company Amidas aromaticas.
CA2358095A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor xa
JP4390024B2 (ja) * 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
CN1390206A (zh) 1999-09-17 2003-01-08 千嬉药品公司 因子Xa的抑制剂
EP1259485B1 (de) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. Benzamide und ähnliche inhibitoren vom faktor xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
DE60130771T2 (de) * 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
EP1379506A2 (de) * 2000-11-28 2004-01-14 Eli Lilly And Company Substituierte carbonsäureamide

Also Published As

Publication number Publication date
EP1273575B1 (de) 2004-05-19
TW575569B (en) 2004-02-11
DK1273575T3 (da) 2004-09-13
ATE340166T1 (de) 2006-10-15
ATE267178T1 (de) 2004-06-15
EP1273575A1 (de) 2003-01-08
KR100739359B1 (ko) 2007-07-18
RU2257381C2 (ru) 2005-07-27
EP1415990B1 (de) 2006-09-20
PL207651B1 (pl) 2011-01-31
CN1319594A (zh) 2001-10-31
KR20010095174A (ko) 2001-11-03
HU0101333D0 (en) 2001-06-28
EP1415990A1 (de) 2004-05-06
DE60103390D1 (de) 2004-06-24
HUP0101333A3 (en) 2002-12-28
BR0101264A (pt) 2001-11-06
AR027985A1 (es) 2003-04-23
CA2395846C (en) 2009-08-11
ES2271464T3 (es) 2007-04-16
AU776053B2 (en) 2004-08-26
CA2395846A1 (en) 2001-10-11
PT1273575E (pt) 2004-09-30
HUP0101333A2 (hu) 2002-02-28
PL346731A1 (en) 2001-10-08
DE60123294T2 (de) 2007-04-05
JP3788349B2 (ja) 2006-06-21
WO2001074791A1 (fr) 2001-10-11
TR200401955T4 (tr) 2004-09-21
US20030195193A1 (en) 2003-10-16
US20040068109A1 (en) 2004-04-08
ES2217129T3 (es) 2004-11-01
DE60103390T2 (de) 2005-06-16
CN1226292C (zh) 2005-11-09
US7307074B2 (en) 2007-12-11
EP1273575A4 (de) 2003-01-08
AU2982701A (en) 2001-10-04
US6642224B1 (en) 2003-11-04
USRE43481E1 (en) 2012-06-19
MXPA01003279A (es) 2004-07-30
AU2001244634A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
DE60123294D1 (de) Diazepan Derivate als Faktor X Inhibitor
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
NO20023424D0 (no) Corticotropin-frigjörende faktor antagonister
EE200300049A (et) Imidasooli derivaadid
NO20021230D0 (no) Inhibitorer for faktor Xa
EE200300175A (et) Tsüanopürrolidiini derivaadid
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
ATE360620T1 (de) Imidazolderivate
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DE60105513D1 (de) Drosselspule
DE50003036D1 (de) Imidazolverbindungen als phosphodiesterase vii-hemmer
ATE285412T1 (de) Thienopyrimidine als phosphodiesterase hemmer
ATE332895T1 (de) Tetrazolderivate
DE60203006D1 (de) Pyrrolidin-derivate als faktor xa inhibitoren
NO20025659L (no) Heterocykliske forbindelser
ID29755A (id) Senyawa-senyawa organosilikon
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
ATE272045T1 (de) Substituierte 1-aminobutan-3-ol-derivate
ATE372338T1 (de) Deshalogenverbindungen
DE50003309D1 (de) Imidazolderivate als phosphodiesterase vii-hemmer
NO20031837D0 (no) Kalsilytiske forbindelser
NO20023508D0 (no) Kalsilyttiske forbindelser
NO20030303D0 (no) Kalsilytiske forbindelser
ATE366244T1 (de) Tetrazolderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition